North America Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables, Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research, Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes, Hospital & Clinics) – Industry Trends and Forecast to 2030.
North America Next Generation Sequencing (NGS) Market Analysis and Size
High-throughput sequencing, most widely regarded as the "next-generation" sequencing (NGS), is now integrated into routine clinical practice due to the numerous technical and functional developments, while early protocols relied on samples harvested outside of typical workflows in clinical pathology, standard formalin-fixed, paraffin-embedded specimens which can be used more regularly as starting material for NGS.
Data Bridge Market Research analyzes that the North America next generation sequencing (NGS) market, which was USD 3489.40 million in 2022, will reach USD 15615.61 million by 2030 and is expected to undergo a CAGR of 17.4% during the forecast period. The “consumables” segment dominates the product type segment of the market due to increasing incidence of neurological disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product (Instruments, Consumables, Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research, Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes, Hospital & Clinics)
|
|
Countries Covered
|
U.S., Canada, Mexico
|
|
Market Players Covered
|
Agilent Technologies, Inc. (U.S.), ThermoFisher Scientific, Inc. (U.S.), QIAGEN (Netherlands), llumina, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), BGI (A subsidiary of BGI Group) (China), Oxford Nanopore Technologies plc (U.K.), Illumina, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), 10x Genomics, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Genewiz (U.S.), Partek Incorporated (U.S.), Becton, Dickinson and Company (BD) (U.S.), Genomic Health, Inc. (U.S.), Guardant Health, Inc. (U.S.), Personalis, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Next Generation Sequencing (NGS), also known as high-throughput sequencing, refers to a set of advanced techniques used to determine the nucleotide sequence of DNA (deoxyribonucleic acid) or RNA (ribonucleic acid) molecules. Unlike traditional Sanger sequencing methods, which were time-consuming and limited in scalability, NGS allows for the rapid and parallel sequencing of millions of DNA fragments.
North America Next Generation Sequencing (NGS) Market Dynamics
Drivers
- Advancements in Genomic Research
The continuous advancements in genomic research and technology have propelled the demand for NGS. Researchers use NGS techniques to study complex genetic variations, enabling discoveries in personalized medicine, rare diseases, and cancer genomics.
- Falling Sequencing Costs
The cost of sequencing has significantly decreased over the years, making NGS more accessible to researchers and healthcare providers. This reduction in costs encourages widespread adoption, especially in clinical settings.
- Rising Applications in Clinical Diagnostics
NGS is increasingly utilized for clinical diagnostics, including cancer screening, prenatal testing, and rare disease identification. The expanding scope of applications in healthcare drives market growth.
Opportunities
- Oncology Diagnostics
NGS plays a crucial role in cancer genomics, aiding in targeted therapies, identifying biomarkers, and predicting treatment responses. The expanding field of oncology diagnostics offers significant growth opportunities.
- Population Genomics and Precision Medicine
Large-scale population genomics projects enable researchers to understand genetic variations in diverse populations. NGS contributes to precision medicine initiatives by tailoring treatments based on individual genetic profiles.
Restraints/ Challenges
- Data Management and Analysis
NGS generates massive amounts of data, requiring robust computational resources and bioinformatics expertise for efficient data management, analysis, and interpretation. Handling and storing large datasets present challenges.
- Regulatory Challenges
NGS technologies are subject to stringent regulations, especially in clinical applications. Compliance with regulatory standards, including data privacy laws, can be complex and time-consuming.
This next generation sequencing (NGS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the next generation sequencing (NGS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In October 2021, ThermoFisher Scientific Inc. announced that it has launched Applied Biosystem QuantSudio Absolute Q-Digital PCR System, which is a designed to provide highly accurate results in genetic analysis. The digital PCR is already in use for monitoring cancer driven mutations in liquid biopsy. This has helped he company to increase its product portfolio
North America Next Generation Sequencing (NGS) Market Scope
The next-generation sequencing (NGS) market is segmented on the basis of product, application, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Instrument
- Consumables
- Services
Application
- Diagnostic
- Drug Discovery
- Biomarker Discovery
- Precision Medicine
- Agriculture and Animal Research
End User
- Hospitals & Clinics
- Research Centers and Academic & Government Institutes
- Pharmaceutical & Biotechnology Companies
North America Next Generation Sequencing (NGS) Market Region Analysis/Insights
The next generation sequencing (NGS) market is analyzed and market size insights and trends are provided by country, product, application, and end user as referenced above.
The countries covered in the market report are U.S., Canada, and Mexico.
The U.S. is expected to dominate and be the fastest-growing country in the market due to rising advancements in research activities. Also, due to higher investment and funding processes between the public-private partnerships.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like downstream and upstream value chain analysis, technical trends, and Porter’s five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and the challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the region data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The next generation sequencing (NGS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for next generation sequencing (NGS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on next generation sequencing (NGS) market. The data is available for historic period 2010-2020.
Competitive Landscape and North America Next Generation Sequencing (NGS) Market Share Analysis
The next generation sequencing (NGS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to next generation sequencing (NGS) market research.
Some of the major players operating in the next generation sequencing (NGS) market are:
- Agilent Technologies, Inc. (U.S.)
- ThermoFisher Scientific, Inc. (U.S.)
- QIAGEN (Netherlands)
- Illumina, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- BGI (A subsidiary of BGI Group) (China)
- Oxford Nanopore Technologies plc (United Kingdom)
- Illumina, Inc. (U.S.)
- Pacific Biosciences of California, Inc. (U.S.)
- 10x Genomics, Inc. (U.S.)
- PerkinElmer, Inc. (U.S.)
- Genewiz (U.S.)
- Partek Incorporated (U.S.)
- Becton, Dickinson and Company (BD) (U.S.)
- Genomic Health, Inc. (U.S.)
- Guardant Health, Inc. (U.S.)
- Personalis, Inc. (U.S.)
SKU-